Drug Profile
Lu AE 04621
Alternative Names: Lu AE04621Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Lundbeck A/S
- Class Antiparkinsonians
- Mechanism of Action Dopamine modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for phase-I development in Parkinson's-disease in USA (PO, Liquid)
- 01 Dec 2016 Lundbeck completes a phase I trial in Parkinson's disease in USA (PO) (NCT02649608)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in Denmark (PO, Liquid)